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Abstract  
Introduction: The Nordic countries have comprehensive, population-based health and medical 
registries linkable on individually unique personal identity codes, enabling complete long-term 
follow-up. The aims of this study were to describe the NorTwinCan cohort established in 2010 and 
assess whether the cancer mortality and incidence rates among Nordic twins are similar to those in 
the general population.  
Methods: We analysed approximately 260,000 same-sexed twins in the nationwide twin registers 
in Denmark, Finland, Norway, and Sweden. Cancer incidence was determined using follow up 
through the national cancer registries. We estimated standardize incidence (SIR) and mortality 
(SMR) ratios with 95% confidence intervals (CI) across country, age, period, follow-up time, sex 
and zygosity.  
Results: More than 30,000 malignant neoplasms have occurred among the twins through 2010.  
Mortality rates among twins were slightly lower than in the general population (SMR 0.96; CI 95% 
0.95-0.97) but depends on information about zygosity.  Twins have slightly lower cancer incidence 
rates than the general population, with SIRs of 0.97; (95% CI 0.96-0.99) in men and 0.96; (95% CI 
0.94-0.97) in women. Testicular cancer occurs more often among male twins than singletons (SIR 
1.15; 95% CI 1.02-1.30), while cancers of the kidney, (SIR 0.82; 0,95% CI 0.76-0.89) lung (SIR 
0.89; 95% CI 0.85-0.92), and colon (SIR 0.90; 95% CI 0.87-0.94) occur less often in twins than in 
the background population.  
Conclusion: Our findings indicate that the risk of cancer among twins is so similar to the general 
population that cancer risk factors and estimates of heritability derived from the Nordic twin 
registers are generalizable to the background populations.  
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Introduction   
Genetic and environmental factors contribute to the aetiology of cancer. Joint estimates of the 
heritability of the most common cancers based on the large twin cohorts in Denmark, Finland 
and Sweden were first published in 2000 (Lichtenstein et al. 2000). We expanded this analysis 
with the addition of data from Norway, extended the follow-up time, improved statistical 
methodology and tripled the number of twins with cancer. Hence, a sufficient number of cases 
had occurred to provide more accurate estimates for common cancers and reliable estimates 
for less common cancers (Mucci et al. 2016). The purpose of this paper is two-fold. First, it 
describes the twin registers in the four countries participating in the Nordic Twin Study of 
Cancer (NorTwinCan) as a general reference for specific studies based on these registers. 
Second, it assesses whether the cancer mortality and incidence rates among individuals in the 
Nordic twin registers are similar to those in the general population.  
While more than 2,000 articles have been published based on these four Nordic twin registers 
during the past 30 years [PubMed search November 2016], the features of cancer risk pattern 
among twins compared to the population have not been systematically analysed. For 
individual cancers, we have explored cancer risk among twins for prostate, breast, colorectal 
and lung cancer (Hjelmborg et al. 2014, 2016, Mucci et al. 2016). This paper, however, 
includes systematic descriptions of the participating twin registers: background, organisation, 
size, years of record collection, and administrative aspects that determine internal and external 
validity. We assessed whether twins have the same mortality profile as the general population 
to reveal possible selection issues of those included in the twin registers. Infant mortality rates 
are higher among twins than singletons (Farooqui et al. 1973; Keith 1994) but from childhood 
onwards, there is no reason to assume differential mortality between twins and non-twins 
(Christensen et al. 1995, Kaprio 2013).  
To assess our a priori hypothesis that the rates of cancer mortality and cancer incidence among 
twins do not differ from those in the general population, we conducted comprehensive analyses 
of standardized mortality ratios (SMR) for overall mortality across country, age, period, 
follow-up years and of overall cancer and site-specific standardised incidence ratio (SIR) 
analyses across country, period, age, sex and zygosity.  
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Methods  
 
Participating twin registers 
The NorTwinCan network consists of twin registers in Denmark, Finland, Norway and 
Sweden (Table 1). These registers are independent research entities but committed to 
collaborative studies by working to harmonise policies for quality assurance, logistics and 
study designs as well as for permission and terms of collaboration. Since the mid-20th 
century, every citizen in the Nordic countries has been assigned an individually unique 
personal identity code (PIC), which is used in population registration and throughout the 
national health care systems. These codes enable complete follow-up through record linkage 
to ascertain vital status, addresses, health outcomes, migration and death.  Research projects 
using the twin registers need appropriate permissions from both the national Data Protection 
Authorities, regional ethics committees and from the boards of the twin registers.  
In all four of the Nordic twin registries zygosity classifications is based on questionnaire 
methodology relying on responses from the same-sexed twins to items about their similarity 
(Cederlöf et al. 1961; Sarna et al. 1978). This method classifies zygosity correctly in more 
than 95% of the same-sexed twin pairs when compared to zygosity determination based on 
genetic markers (Sarna et al. 1978, Christiansen et al. 2003, Harris et al. 2006). Zygosity 
assessment by genetic markers has been used increasingly due to lower cost, and by 2016 
zygosity has been defined by genetic markers for more than 10,000 thousand twin pairs.  
 
Denmark 
Established in 1954 the Danish Twin Registry is the oldest population based twin register 
covering twins born since 1870. The twin cohorts were ascertained in four waves using 
different methods as previously described in detail (Skytthe et al. 2002; Skytthe et al. 2011). 
At present approximately 175,000 twin individuals have been included in the entire twin 
registry, although the NorTwinCan study included a subset. Vital status and emigration status 
are obtained through yearly linkage to the national civil registration system. In the current 
study twin pairs with both twins alive on January 1, 1943 or born thereafter are included. 
 
Finland 
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The Finnish Twin Cohort Study was initiated in the early 1970s. Twins were ascertained in 
1974 based on selection from Central Population Register of all pairs of persons born on the 
same date, of the same sex, in the same parish, and with the same surname at birth. The 
selection was restricted to persons born before 1958. A questionnaire was mailed to all 
potential twins aged 18 years or more in pairs with both twins alive in 1975 identifying more 
than 16000 like-sexed twin pairs, of which zygosity was known at baseline for 13,888, based 
on responses to questionnaires mailed in 1975. Not all pairs could be classified reliably as MZ 
or DZ, so twins of unknown zygosity may be due to this or to lack of response (Sarna et al, 
1978).  Persons who were not biological twins but satisfied the selection criteria were 
excluded based on the questionnaire response or after inquiries to local parishes as previously 
described in detail (Kaprio et al. 1978; Kaprio & Koskenvuo 2002). The Finnish Twin Cohort 
has been repeatedly linked with the Central Population Register to obtain data on death and 
emigration. In this study only same-sex twin pairs born 1890-1957 are included. In the late 
1990s, the twin cohort was expanded to include also opposite-sex twins born between 1940 
and 1957, however comprehensive inclusion of opposite-sex pairs was possible for pairs born 
1950-1957 only. 
 
Norway 
The Norwegian Twin Registry was established in 2009, as a merger of three Twin Panels, 
covering respectively birth years 1895-1945, 1915-1960 and 1967-1979 as described in detail 
elsewhere (Bergen, 2002; Harris et al. 2002; Harris et al. 2006; Nilsen et al. 2012). Twins 
born before 1960 had to be alive in 1960 for assignment of national PIC introduced in 1964, 
based on the 1960 national census. Twins born after 1967 were registered in the medical birth 
registry, complete from 1967 onwards. The registry has information on 48,008 twins, of 
whom 31,362 have provided consent. As linkage to Norwegian registers including the Cancer 
Registry requires consent from twins, twin pairs where one or both twins are non-consenting 
twins have been excluded in this study. Data from the Norwegian Twin Registry have been 
matched with information from the National Cause of Death Registry (with complete data in 
electronic format from 1951 onwards). 
 
Sweden 
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Compiled in several waves, the initial Swedish twin cohort was comprised of twins born 
1886-1925 who were identified by investigators beginning in the 1960s from local parish 
registers. In 1961, a questionnaire was sent to all same-sexed twin pairs with both twins alive 
and living in Sweden. If both twins in a pair responded the twin pair was included in the 
register. Information about opposite-sexed twin pairs from these cohorts was added 
subsequently in late 1990s. Twins born 1926-1958 were identified in 1970 from national birth 
registers, and a questionnaire was sent to all pairs alive and living in Sweden 1973. Younger 
twin cohorts have only recently been contacted as part of different studies, in which zygosity 
was assessed for same-sex twins (Magnusson et al. 2013). Data on death and emigration have 
been obtained on regular basis through linkage to the population register and the Swedish 
Mortality Register. 
 
Study sample 
For the comparisons of standard incidence and mortality ratios, we restricted these analyses to 
same-sexed twins for several reasons. First, only opposite-sexed twins born 1950-1957 would 
be comprehensively available from Finland. Second, no opposite-sexed twins from the birth 
cohorts 1911-1930 are registered in the Danish Twin Registry. Third, only deceased opposite-
sexed twins from Norway were present from birth cohorts before 1960, and among younger 
birth cohorts opposite-sexed twins were included during 1967 to 1976. Fourth, the Swedish 
opposite-sexed twins born before 1926 were incompletely represented. Opposite-sex pairs 
studied by Ahrenfeldt et al. 2016, showed no evidence for differences in cancer risk between 
OSDZ and SSDZ pairs.  
 
 
Cancer incidence 
The twin data were linked to the national cancer registries in each country to identify twins 
with one or more cancer diagnoses since enrolment in the twin register. The linkages were 
conducted in 2011-2012 when cancer registration was complete through 2010 for Finland, 
2009 for Denmark and Sweden, and 2008 for Norway. Updated linkages currently underway 
will substantially increase the number of cancer cases. The Danish Cancer Registry holds 
information on tumours diagnosed since 1943, the Finnish and Norwegian Cancer Registries 
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since 1953, and the Swedish Cancer Registry since 1958 (Pukkala et al. 2018). Cancer 
registration is virtually complete with more than 98% of all known tumours included in the 
register in Denmark (, Finland and Norway. In Sweden, cancer cases are not traced via 
information in death certificates which has caused incompleteness of about 4% of all cancer 
sites and a much higher percentage of incompleteness of some cancer types with short 
survival (Mattsson, 1984).  
 
Follow-up  
The twin registers are also followed for vital status and emigration through national registers 
in each country on causes of death and the central population registers for vital status. To 
calculate person-years at risk of death and incident cancer, follow-up started at various dates 
depending on the methods of ascertainment in each of the four cohorts (Supplemental Table 
S1). Follow-up ended at death, at date of emigration, or at the common closing date of follow 
up (31 December 2008 for Norway and Sweden, 31 December 2009 for Denmark, and 31 
December 2010 for Finland). 
 
Statistical methods 
To assess whether mortality and cancer incidence in the population-based twin cohorts is 
representative of their respective background populations, the numbers of observed deaths, 
cancer cases and person-years at risk were counted for five-year calendar periods, by sex, and 
five-year age groupings.  
The standardized mortality ratio (SMR) for overall mortality was defined as the ratio of the 
observed to expected number of deaths. The expected numbers of deaths were calculated by 
multiplying the number of person-years in each stratum by the corresponding reference 
mortality rate downloaded from the Human Mortality Database (www.mortality.org). 
Due to different cancer coding schemes in the four national cancer registers, we used the 
NORDCAN grouping of cancer diagnoses into 40 cancer sites to compare incidences across 
the four countries over time (Engholm et al. 2010).  
The standardized incidence ratio (SIR) was defined as the ratio of the observed to expected 
number of cancer cases. The expected numbers of cases for total cancer and for the specific 
cancer types were calculated by multiplying the number of person-years in each stratum by 
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the corresponding cancer incidence rate in the national population was obtained from the 
NORDCAN database. The NORDCAN database incidences are not adjusted for competing 
risk of death from other causes and hence underestimates the true incidence in each stratum. 
Analyses adjusting for competing risks of death have been implemented in other papers from 
NorTwinCan. For the 95% confidence intervals (CI) of the SMR and SIR estimates it was 
assumed that the number of observed cases followed a Poisson distribution. 
 
Results 
More than 260,000 persons from same-sexed twin pairs in the Nordic twin registers were 
included and the accumulated number of person-years was 6.65 million (Table 1). The mean 
length of follow-up was 25.5 years. Zygosity was known for 78% of twin pairs; the main 
reason for missing data were the unavailability of the twins (deaths or missing address data) 
or lack of response to questionnaires. Of those with known zygosity, 39% were monozygous 
twins. The birth year distribution of the twins in each national twin cohort is described in 
Supplemental Figure S1. 
 
Overall mortality 
The SMR during a twin’s first year of life was 4.44 (95% CI 4.23-4.67), reflecting the high-risk 
nature of twin pregnancies. The SMRs estimates, excluding the first year of life, were between 
0.93 and 0.99 in all countries (Table 2). The SMR for all countries combined varied from 0.89 
in monozygotic twins to 1.28 in the twins with unknown zygosity (Table 3), with similar 
results in each of the four countries. The higher SMRs in twins with unknown zygosity 
reflects the higher rates of substance use, smoking and psychiatric problems among non-
responders to health surveys. 
Supplemental Figure S2 shows the distributions for SMR by age, birth year, period, and 
follow up time. Danish twins had a mortality similar to the general population during the 
whole period. The age pattern shows only minor deviations from the expected values of SMR, 
and this also applies to the birth cohort pattern.  
Mortality in the Finnish twin cohort is also similar to the general population except for a 
slightly lower mortality in the beginning of the period. This pattern is found in all cohorts, 
especially among twins with known zygosity (Supplemental Figure S3). The longer the time 
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since follow-up began the closer the SMR comes to 1 indicating that left-truncation or the 
selection of both twins in a pair being alive at initiation of follow-up may entail oversampling 
of individuals with a lower mortality rate. 
Mortality is lower among the Swedish twin cohorts by age, birth year and period for most 
twin categories, especially for the twins with known zygosity.  
The mortality pattern deviates more from that in the general population in the Norwegian and 
Swedish than in the other Nordic twin cohorts. The SMR values among the older Norwegian 
twins are close to 1, but are increasingly lower for the younger cohorts. Low SMR estimates 
are also observed in the beginning of the period most likely due to the “healthy worker effect” 
when both twins in a pair had to be alive for ascertainment at a specific date. Cohorts born 
before 1945 and with unknown zygosity are poorly represented in the data set; cohorts born 
between 1920 and 1945 with unknown zygosity do indeed only include twins that have died. 
Also, left-truncation or the selection of both twins in a pair being alive at initiation of follow-
up may be influential. 
 
Cancer incidence 
The number of cancer cases diagnosed in the study period exceeds 30,000. The observed 
numbers - excluding non-melanoma skin cancer - among both men and women in all twin 
registers were slightly lower than those expected based on the national cancer incidence rates, 
yielding SIRs 0.97; (95% CI 0.96-0.99) in men and 0.96; (95% CI 0.94-0.97) in women (Table 
4). The SIR estimates were below 1.0 in all countries for both sexes, except among Finnish and 
Norwegian men where the estimated SIR was 1.01 and 1.02, respectively and not significantly 
different from unity. Overall cancer incidence was similar for men and women in three of the 
four countries; the exception was Norway, where a marked difference was observed for the 
women (SIR 0.92; 0.87-0.96). The overall SIR for cancer incidence was similar for monozygotic 
(MZ) and dizygotic (DZ) twins in each country (Table 5). 
The SIR estimates for the majority of site-specific cancers were not significantly different from 
1.00 (Table 6). Only male lip, prostate, and testis cancer showed significantly, albeit slightly, 
higher estimates of SIR than 1.00, while no sites among women showed significantly elevated 
estimates. Among men and women, three and seven of 40 sites, respectively showed SIR 
estimates significantly lower than one. No adjustment for multiple testing is made here, but 13 of 
the 80 comparisons are significant at the p<0.05 level, compared to 4 expected.  
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Among the major cancer sites with at least 100 cases, the lowest SIR estimates in both sexes 
were observed for kidney cancer, with SIRs of 0.82 in men and 0.83 in women (Table 6). 
Significantly lower SIR estimates were also seen for colon cancer, SIR values were 0.90 for men 
and 0.87 for women, and for lung cancer 0.88 and 0.95, respectively. Differences emerged when 
comparing the twin cohorts from each country, especially among men (data not shown). SIR 
estimates were significantly greater than 1.0 among the Norwegian men for cancer of the 
pharynx, stomach, larynx, testis, and bone, but none were below 1.0 in this group.  
No difference in SIR estimates is found for cancer in general between twins with known zygosity 
and twins with unknown zygosity – both groups have SIR estimates just below 1. But differences 
do emerge for site-specific cancers (Table 7). The most striking differences are found for lung 
cancer, where the SIR estimate for twins with known zygosity is 0.86 (95% CI 0.82-0.89) and 
1.13 (95% CI 1.02-1.26) for twins with unknown zygosity probably due to non-responders being 
more likely to be smokers, and for prostate cancer the SIR estimates were 1.06 (1.02-1.09) and 
0.85 (0.76-0.95) respectively. This may reflect higher SES status among participants in the twin 
surveys, and higher likelihood to undergo prostate cancer screening in Norway, Sweden and 
Finland. 
For same-sexed twins with known zygosity the site-specific SIR estimates for the MZ and the 
DZ twins are generally close to each other (Table 7). For 20 of the 40 sites investigated, the SIR 
point estimate is greater among the MZ than the DZ twins, and this difference is most 
pronounced for the prostate and testis cancer (prostate: 1.11 (95% CI 1.05-1.17) and 1.03 (95% 
CI 0.99-1.08) for MZ and DZ, respectively; and for testis the values are 1.36 (95% CI 1.12-1.65) 
and 1.08 (95% CI 0.91-1.28) for MZ and DZ, respectively. Other notable sites where MZ values 
were significantly lower than DZ values include colon, pancreas, and lung. In contrast, there 
were no zygosity differences in the SIR estimates for kidney cancer which were significantly 
lower among both MZ and DZ twins.  
 
Discussion 
 
This study reports on mortality and cancer incidence in twin cohorts from four Nordic 
countries with a long tradition of population-based research based on national registers. The 
data comprise information on more than 260,000 twins and enable research into genetic 
influences on the liability to develop specific types of cancer beyond what has previously 
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been possible. Further, the twin design allows studies of environmental causes of cancer while 
accounting for background genetic and familial influences. 
 
The Nordic twin registers are regularly linked with national population registers to update 
information on death. Follow-up for emigration has not always been considered important in 
these studies because its magnitude has remained small but when the follow-up times increase 
the dates of emigration as an end-of-follow-up event should also be systematically linked to 
these twin registers. Even a small proportion of never-dying persons will bias the SMR and 
SIR estimates markedly downward (Pukkala, 2011). Therefore, it is important to link every 
research cohort with the population registry before follow-up studies to confirm that every 
person in the cohort really exists in the population either alive or with date of emigration or 
death.  
The overall mortality rates are 1-5% lower in all four countries among individuals in the 
Nordic twin cohorts than in the general population. These differences can be explained by 
specific periods and/or birth cohorts, for which the ascertainment or the follow-up had 
shortcomings. For example, the Danish twins born from 1953-1982 are identified based on 
information from the population register regarding the relationship between parents and 
children. However, for the birth cohorts 1953-1960 this information is incomplete and 10-
40% of the twin pairs born in this period are not included in the register (Skytthe et al. 2002). 
Likewise, the establishment of the early part of the register in Finland and Sweden, was based 
on the identification of complete twin pairs with both twins alive to be included in surveys 
(Kaprio et al. 1978; Cederlöf et al. 1961). In Norway, twins must consent to be part of the 
NTR research program as a prerequisite for conducting linkages to the National Cancer 
Registry. If only one twin has consented then information from the pair will often be excluded 
from analyses. Still, the overall differences are fairly small, and unlikely to lead to meaningful 
differences. 
In comparison to the general population, mortality is lower among twins with known zygosity 
and significantly higher among twins with unknown zygosity. This most likely reflects bias in 
survey response, which is how zygosity status was determined. Those who participate in 
health surveys tend to have better mental and physical health and a healthier lifestyle than 
non-participants (Nohr et al (2018), Silva et al (2015), Ellenberg (1994)). Notably, smokers 
are less likely to participate in surveys, and this is seen in the SIR differences for lung cancer 
between twin pairs of known and unknown zygosity. In these cohorts, smoking was, 
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expectedly, a strong predictor of lung cancer incidence (Hjelmborg et al. 2017). This bias is 
reflected in a higher risk of premature death and increased risk of cancers that are strongly 
associated with lifestyle factors such as tobacco and alcohol-related cancers.  
The Nordic health data infrastructure and the unique personal identity codes are utilised in all 
important registers to allow electronic linkages of numerous register-based health indicators. 
Data from many other registries may indeed be used as outcome variables or as co-factors for in 
controlling potential confounding. Hospital discharge registries, perinatal outcome registries, 
cause of death registries, registries of infectious diseases and various disease-specific registries 
(diabetes, AIDS, etc), registers of prescribed medications, disability pensions and other 
administrative registers with health-relevant data are commonly used (Christensen et al. 2011; 
Pukkala, 2011). The Nordic cancer registries are also able to produce data for non-standard 
categories based on variables such as morphology and spreading, and for certain precancerous 
lesions (Pukkala et al. 2018). 
 The pattern of incidence across cancer types in the twins tends to reflect that of the general 
population. The overall cancer risk was marginally lower than average across most of the twin 
cohorts. Again, this is most likely due to the response bias whereby participation rates are better 
among healthier and-conscientious subjects. Assessment of zygosity also depends on survey 
participation and hence is a source of potential selection bias. The SIRs varied systematically 
between the groups of twins with known versus unknown zygosity, with higher rates among 
the group with known zygosity for cancers associated with high SES and better lifestyle and 
higher rates among the group with unknown zygosity for cancers associated with low SES 
and more smoking and alcohol use. However, the SIR based on data from all the twins 
combined (those with and without zygosity determination) indicates that twins are highly 
representative of the population overall. The few sites where the twin SIR deviate 
unexpectedly from the population values require further study; for example, there is no 
obvious reason why kidney cancer should be much less common among twins than 
singletons.  
Our study illustrates multiple advantages of combining the twin cohorts in the Nordic 
countries. The increased number of cases facilitates studies of rare cancers that could not be 
conducted based on the data from single countries. Analyses based on greater sample sizes 
yield more precise estimates of familial risk, heritability and the influence of environmental 
factors on cancer liability (Mucci et al. 2016). Increasing the number of monozygotic twin 
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pairs in which only one of the twins has a rare cancer permits studies of environmental factors 
independent of the genetic liability to disease. Such pairs are also extremely valuable for 
epigenetic studies. The long history of similar surveys among twins in the four countries 
facilitate the combination of data from different national surveys to study gene-environment 
interaction as exemplified by a recent study on genetic predisposition to smoking and lung 
cancer (Hjelmborg et al. 2016). Finally, the social and demographic structure in the four 
countries is similar, and a reliable and complete registration of a number of health events and 
conditions is common in the Nordic countries.  
 
Conclusions 
With an annual increase of about 1,600 cancer cases in the twin cohorts defined in this study, we 
estimate after our next linkage to cancer registries with information through 2017 more than 
40,000 cancer cases will be available for further studies of cancer. The high internal validity of 
comparisons within a defined twin register cohort make prospective twin register-based study 
designs preferable for etiological studies. Overall, the population-representativeness is 
excellent, with only a slightly more favourable SMR and SIR profile than in the general 
population. This small deviation from the population values implies that generalization of 
results to entire national populations should be made with some caution. Because the Nordic 
twin registers are committed to work towards joint Quality Assurance standards, including 
defined accessibility to external research data requests, and as the twin registers together 
contain a huge number of prospectively occurring cases of cancer, the NorTwinCan twin 
register cohorts provide a solid basis for prospective studies on cancer causes and control as 
well as opportunities to explore factors that influence cancer using multiple study designs 
made possible with twin data (Boomsma et al, 2002).  
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Table 1. Characteristics of the NorTwinCan cohort of twins from same-sexed twin pairs with follow-
up for cancer incidence. MZ = Monozygotic twins, DZ = Dizygotic twins, UZ = Unknown zygosity 
 
Country Denmark Finland Norway Sweden Total 
Birth cohorts 1870-2004 1880-1957 1895-1979 1886-2000  
N individual twins  92,108 28,184 25,804 114,652 260,748 
N (%) MZ twins 24,786 (27) 7,712 (27)  10,690 (42) 37,121 (32) 80,309 (31) 
N (%) DZ twins 43,534 (47) 16,949 (60) 12,993 (50) 49,906 (44) 123,382 (47) 
N (%) UZ twins 23,788 (26) 3,523 (13) 2,121 (8) 27,625 (24) 57,057 (22) 
N (%) female twins  44,618 (48) 13,991 (50) 13,436 (52) 58,559 (51) 130,604 (50) 
First date of follow-up Jan 1943 May 1976 Jan 1964 Jan 1962  
Median age at start of follow-
up, years 
4.6 32.3 31.3 29.2 24.4 
End of follow-up Dec 2009 Dec 2010 Dec 2008 Dec 2009  
Person years 2,886,920 838,218 602,621 2,322,556 6,650,315 
Median follow-up time, years  
35.7 34.7 27.8 19.1 28.3 
N (%) Deaths 22,588 (25) 8,852 (31) 5,464 (21) 25,618 (22) 62,522 (24) 
N incident cancer cases 9,885 4,582 3,436 12,308 30,211 
 
 
 
 
19 
Table 2. Observed (O) and expected (E) numbers of deaths, and standardised mortality ratios (SMR 
= O/E) with 95% confidence intervals (CI) among same-sexed twins in the Nordic twin registers, by 
country and sex. First year of life is excluded. 
 
Country 
Males  Females 
O E SMR 95% CI  O E SMR 95% CI 
Denmark 10,996 11,231 0.98 0.96-1.00  10,180 10,368 0.98 0.96-1.00 
Finland 4,959 5,215 0.95 0.93-0.98  3,893 4,106 0.95 0.92-0.98 
Norway 3,331 3,407 0.98 0.95-1.01  2,133 2,282 0.94 0.90-0.98 
Sweden 12,469 13,308 0.94 0.92-0.95  13,000 13,492 0.96 0.95-0.98 
All 31,755 33,161 0.96 0.95-0.97  29,206 30,248 0.97 0.95-0.98 
 
 
 
 
Table 3. Observed (O) and expected (E) numbers of deaths, and standardised mortality ratios (SMR 
= O/E) with 95% confidence intervals (CI) among same-sexed twins in the Nordic twin registers, by 
zygosity. First year of life is excluded. MZ = Monozygotic twins, DZ = Dizygotic twins, UZ = 
Unknown zygosity 
 
Zygosity 
All countries 
O E SMR 95% CI 
MZ 18,108 20,385 0.89 0.88-0.90 
DZ 34,331 36,420 0.95 0.94-0.96 
UZ 8,422 6,604 1.28 1.25-1.30 
All 60,961 63,409 0.96 0.95-0.97 
 
 
 
Table 4. Observed (O) and expected (E) numbers of cancer cases (all sites but non-melanoma skin 
cancer), and standardised incidence ratios (SIR = O/E) with 95% confidence intervals (CI) among 
same-sexed twins in the Nordic twin registers, by country, and sex. 
 
Country 
Males  Females 
O E SIR 95% CI  O E SIR 95% CI 
Denmark 4,494 4,701 0.96 0.93-0.98  4,953 5,122 0.97 0.94-0.99 
Finland 2,351 2,325 1.01 0.97-1.05  2,119 2,179 0.97 0.93-1.01 
Norway 1,787 1,755 1.02 0.97-1.07  1,509 1,645 0.92 0.87-0.96 
Sweden 5,626 5,906 .095 0.93-0.98  6,204 6,508 0.95 0.93-0.98 
All 14,258 14,687 0.97 0.96-0.99  14,785 15,454 0.96 0.94-0.97 
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Table 5. Observed (O) and expected (E) numbers of cancer cases (all sites but non-melanoma skin cancer), and standardised incidence ratios 
(SIR = O/E) with 95% confidence intervals (CI) among same-sexed twins in the Nordic twin registers, by country, and zygosity. 
 
Country 
MZ  DZ  UZ 
O E SIR 95% CI  O E SIR 95% CI  O E SIR 95% CI 
Denmark 2,924 3,067 0.95 0.92-0.99  5,575 5,772 0.97 0.94-0.99  948 984 0.96 0.90-1.03 
Finland 1,266 1,236 1.02 0.97-1.08  2,686 2,719 0.99 0.95-1.03  518 550 0.94 0.86-1.03 
Norway 1,170 1,199 0.98 0.92-1.03  1,520 1,619 0.94 0.89-0.99  606 582 1.04 0.96-1.13 
Sweden 4,069 4,237 0.96 0.93-0.99  6,875 7,234 0.95 0.93-0.97  886 943 0.94 0.88-1.00 
All 9,429 9,739 0.97 0.95-0.99  16,656 17,344 0.96 0.95-0.98  2,958 3,058 0.97 0.93-1.00 
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Table 6. Observed (O) and expected (E) numbers of cancer cases diagnosed by end of follow up among same-sexed twins in the Nordic twin 
registers, –by sex. Expected numbers based on national population; standardised incidence ratios (SIR = O/E) with 95% confidence intervals 
(CI).  
Cancer site (ICD O-10 code) 
Males  Females 
O E SIR 95% CI  O E SIR 95% CI 
 1. Lip (C00)  148   125 1.18 1.01-1.39    22   30 0.72 0.48-1.10 
 2. Tongue (C01-02)   55    65 0.85 0.65-1.10    35   41 0.85 0.61-1.19 
 3. Mouth (C03-06+C46.2)   29    36 0.80 0.55-1.15    39   37 1.06 0.77-1.45 
 4. Salivary glands (C07-08)   83    90 0.92 0.74-1.14    67   62 1.06 0.85-1.37 
 5. Pharynx (C09-14)  140   130 1.07 0.91-1.27    45   49 0.93 0.69-1.24 
 6. Oesophagus (C15)  206   208 0.99 0.87-1.14   107   93 1.16 0.96-1.40 
 7. Stomach (C16)  736   713 1.03 0.96-1.11   475  486 0.98 0.89-1.07 
 8. Small intestine (C17)   52    63 0.82 0.63-1.08    52   58 0.90 0.68-1.18 
 9. Colon (C18)  971  1,054 0.92 0.87-0.98  1,100 1,238 0.89 0.84-0.94 
10. Rectum and anus  (C19-21)  801   811 0.99 0.92-1.06   601  667 0.90 0.83-0.98 
11. Liver  (C22)  214   211 1.02 0.89-1.16   156  146 1.07 0.92-1.25 
12. Gallbladder and extrahepatic bile ducts  (C23-24)   98   111 0.88 0.73-1.08   243  225 1.08 0.95-1.22 
13. Pancreas (C25)  418   451 0.93 0.84-1.02   439  453 0.97 0.88-1.06 
14. Nose, sinuses (C30-31)   46    36 1.27 0.95-1.70    22   24 0.92 0.61-1.40 
15. Larynx (C32)  166   183 0.91 0.78-1.05    34   31 1.09 0.78-1.52 
16. Lung (incl. trachea and bronchus) (C33-34) 1,739  2,000 0.87 0.83-0.91   924 1005 0.92 0.86-0.98 
17. Pleura  (C38.4+C45.0)   55    67 0.82 0.63-1.07    12   17 0.69 0.39-1.21 
18. Breast (C50)   18    25 0.73 0.46-1.16  4,295 4,273 1.01 0.98-1.04 
19. Cervix uteri (C53)           614  653 0.94 0.87-1.02 
20. Corpus uteri (C54)           851  923 0.92 0.86-0.99 
21. Uterus. other (C55+C58)            66   65 1.01 0.80-1.29 
22. Ovary and uterine adnexa (C56,C57.0-4)           768  813 0.94 0.88-1.01 
23. Other female genital organs (C51-52,C57.7-9)           148  148 1.00 0.85-1.17 
24. Prostate (C61)  3,556  3,442 1.03 1.00-1.07      
25. Testis (C62)   253   220 1.15 1.02-1.30      
26. Penis and other male genital organs (C60+C63)    50    53 0.94 0.72-1.25      
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27. Kidney (C64)   375   456 0.82 0.74-0.91  274 332 0.83 0.73-0.93 
28. Bladder, ureter, urethra (C65-68+D09.0+D41.4)  1,176  1,140 1.03 0.97-1.09  413 424 0.97 0.88-1.07 
29. Melanoma of skin (C43)   478   509 0.94 0.86-1.03  565 576 0.98 0.90-1.07 
30. Skin, non-melanoma (C44+C46.0)   654   692 0.95 0.88-1.02  514 534 0.96 0.88-1.05 
31. Eye (C69)    57    45 1.28 0.99-1.66   49  43 1.15 0.87-1.52 
32. Brain, central nervous system (C70-72+D32-33+D42-43)   429   450 0.95 0.87-1.05  549 540 1.02 0.94-1.11 
33. Thyroid (C73)    65    71 0.92 0.72-1.17  170 197 0.86 0.74-1.00 
34. Bone (C40-41)    35    37 0.94 0.67-1.31   25  29 0.85 0.58-1.26 
35. Soft tissues (C49+C46.1)   103    98 1.06 0.87-1.28   90  89 1.01 0.82-1.24 
36. Non-Hodgkin lymphoma (C82-85,C96)   456   466 0.98 0.89-1.07  365 408 0.89 0.81-0.99 
37. Hodgkin lymphoma ( C81)    84    97 0.87 0.70-1.07   52  67 0.78 0.59-1.02 
38. Multiple myeloma (C90)   196   192 1.02 0.89-1.17  140 170 0.82 0.70-0.97 
39. Acute leukaemia (C91.0+C92.0+C93.0+C94.0+C95.0)   124   146 0.85 0.71-1.02  122 133 0.92 0.77-1.10 
40. Other leukaemia (C91-C95\C9X.0)   258   262 0.98 0.87-1.11  185 183 1.01 0.88-1.17 
          
41. All sites but non-melanoma skin 14,258 14,687 0.97 0.96-0.99  14,785 15,454 0.96 0.94-0.97 
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Table 7. Observed (O) and expected (E) numbers of cancer cases diagnosed by end of follow up among same-sexed twins by zygosity in the 
Nordic twin registers. Expected numbers based on national population; standardised incidence ratios (SIR = O/E) with 95% confidence 
intervals (CI). MZ = Monozygotic twins, DZ = Dizygotic twins, UZ = Unknown zygosity. 
Cancer site (ICD O-10 code) MZ  DZ  UZ 
 O E SIR 95% CI  O E SIR 95% CI  O E SIR 95% CI 
 1. Lip (C00)   56   49 1.15 0.88-1.49   100   89 1.12 0.92-1.37    14  18 0.79 0.47-1.33 
 2. Tongue (C01-02)   26   34 0.77 0.52-1.13    54   61 0.88 0.68-1.15    10  11 0.89 0.48-1.66 
 3. Mouth (C03-06+C46.2)   27   24 1.14 0.79-1.67    38   42 0.90 0.66-1.24     3   7 0.40 0.13-1.24 
 4. Salivary glands (C07-08)   38   48 0.79 0.57-1.08    94   88 1.07 0.87-1.30    18  16 1.16 0.73-1.84 
 5. Pharynx (C09-14)   56   57 0.99 0.76-1.28    90  104 0.87 0.71-1.70    39  19 2.08 1.52-2.85 
 6. Oesophagus (C15)   87   95 0.92 0.75-1.14   184  174 1.06 0.92-1.22    42  32 1.32 0.98-1.79 
 7. Stomach (C16)  366  380 0.96 0.87-1.07   681  675 1.01 0.94-1.09   164 144 1.14 0.98-1.33 
 8. Small intestine (C17)   32   40 0.81 0.57-1.14    59   70 0.84 0.65-1.09    13  11 1.13 0.66-1.95 
 9. Colon (C18)  643  744 0.86 0.80-0.93  1,223 1,323 0.92 0.87-0.98   205 225 0.91 0.79-1.04 
10. Rectum and anus  (C19-21)  470  476 0.99 0.90-1.08   799  851 0.94 0.88-1.01   133 152 0.88 0.74-1.04 
11. Liver  (C22)  125  113 1.10 0.92-1.31   213  208 1.02 0.89-1.17    32  34 0.93 0.66-1.31 
12. Gallbladder and extrahepatic bile ducts  (C23-24)  112  109 1.03 0.86-1.24   190  197 0.96 0.84-1.11    39  30 1.29 0.94-1.76 
13. Pancreas (C25)  244  287 0.85 0.75-0.96   520  523 0.99 0.91-1.08    93  93 1.00 0.81-1.22 
14. Nose, sinuses (C30-31)   21   19 1.10 0.72-1.69    36   35 1.04 0.75-1.45    11   6 1.71 0.95-3.08 
15. Larynx (C32)   57   67 0.86 0.66-1.11   115  125 0.92 0.77-1.11    28  23 1.21 0.84-1.75 
16. Lung (incl. trachea and bronchus) (C33-34)  786  950 0.83 0.77-0.89  1,526 1,745 0.87 0.83-0.92   351 310 1.13 1.02-1.26 
17. Pleura  (C38.4+C45.0)   24   26 0.91 0.61-1.35    38   49 0.77 0.56-1.06     5   9 0.56 0.23-1.35 
18. Breast (C50) 1,437 1,430 1.01 0.95-1.06  2,527 2,489 1.02 0.98-1.06   349 379 0.92 0.83-1.02 
19. Cervix uteri (C53)      211  219 0.96 0.84-1.10   332  375 0.89 0.80-0.99    71  58 1.21 0.96-1.53 
20. Corpus uteri (C54)      291  304 0.96 0.85-1.08   495  540 0.92 0.84-1.00    65  79 0.82 0.64-1.04 
21. Uterus. other (C55+C58)       24   22 1.10 0.74-1.64    36   38 0.95 0.69-1.32     6   5 1.10 0.49-2.45 
22. Ovary and uterine adnexa (C56,C57.0-4)      247  269 0.92 0.81-1.04   436  473 0.92 0.84-1.01    85  72 1.19 0.96-1.47 
23. Other female genital organs (C51-52,C57.7-9)       47   49 0.96 0.72-1.28    86   86 1.00 0.81-1.23    15  13 1.12 0.68-1.86 
24. Prostate (C61) 1,207 1,092 1.11 1.05-1.17  2,023 1,966 1.03 0.99-1.08   326 384 0.85 0.76-0.95 
25. Testis (C62)  100   74 1.36 1.12-1.65   129  120 1.08 0.91-1.28    24  27 0.89 0.60-1.32 
26. Penis and other male genital organs (C60+C63)   15   17 0.89 0.54-1.47    34   30 1.13 0.80-1.58     1   6 0.17 0.02-1.21 
27. Kidney (C64)  207  250 0.83 0.72-0.95   379  456 0.83 0.75-0.92    63  81 0.77 0.60-0.99 
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28. Bladder, ureter, urethra (C65-68+D09.0+D41.4)  518  500 1.04 0.95-1.13   904  907 1.00 0.93-1.06   167 158 1.06 0.91-1.23 
29. Melanoma of skin (C43)  365  363 1.00 0.91-1.11   599  615 0.97 0.90-1.05    79 105 0.75 0.60-0.93 
30. Skin, non-melanoma (C44+C46.0)  428  400 1.07 0.97-1.18   643  706 0.91 0.84-0.98    97 120 0.81 0.66-0.98 
31. Eye (C69)   34   28 1.23 0.88-1.72    64   49 1.30 1.02-1.66     8  10 0.77 0.39-1.54 
32. Brain, central nervous system (C70-72+D32-33+D42-43)  345  320 1.08 0.97-1.20   532  560 0.95 0.87-1.03   101 109 0.93 0.77-1.13 
33. Thyroid (C73)   85   90 0.95 0.77-1.17   135  152 0.89 0.75-1.05    15  26 0.58 0.35-0.96 
34. Bone (C40-41)   20   21 0.94 0.61-1.46    35   36 0.97 0.70-1.35     5   9 0.54 0.22-1.29 
35. Soft tissues (C49+C46.1)   59   60 0.98 0.76-1.27   110  106 1.04 0.86-1.25    24  21 1.15 0.77-1.72 
36. Non-Hodgkin lymphoma (C82-85,C96)  256  280 0.91 0.81-1.03   477  504 0.95 0.87-1.04    88  90 0.98 0.79-1.20 
37. Hodgkin lymphoma ( C81)   57   53 1.07 0.82-1.38    69   97 0.76 0.60-0.96    10  20 0.50 0.27-0.94 
38. Multiple myeloma (C90)  116  116 1.00 0.84-1.20   175  208 0.84 0.73-0.98    45  38 1.17 0.87-1.57 
39. Acute leukaemia (C91.0+C92.0+C93.0+C94.0+C95.0)   77   86 0.90 0.72-1.12   139  151 0.92 0.78-1.09    30  42 0.72 0.51-1.03 
40. Other leukaemia (C91-C95\C9X.0)  139  143 0.98 0.83-1.15   266  255 1.04 0.92-1.18    38  47 0.81 0.59-1.11 
               
41. All sites but non-melanoma skin 9,429 9,739 0.97 0.95-0.99  16,656 17,344 0.96 0.95-0.98  2,958 3,058 0.97 0.93-1.00 
 
 
 
